Cephalon Acquires Swiss Pharmaceutical Company Mepha
Cephalon said that the purchase price paid at closing, inclusive of certain closing adjustments, was CHF662.4m. The purchase price is also subject to further post-closing working capital and
The US Food and Drug Administration (FDA) has approved two Jazz Pharmaceuticals regimens containing Ziihera (zanidatamab-hrii) for the first-line treatment of adults with unresectable, locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal adenocarcinoma (GEA).